Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting

Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting

BackgroundInetetamab is a novel recombinant humanized anti-Human epidermal growth factor receptor 2 (HER2) monoclonal antibody. This real-world retrospective study assessed the efficacy and safety of inetetamab-containing regimens in first-line/second-line treatment of HER2-positive metastatic breas...

Full description

Saved in:
Bibliographic Details
Main Authors: Jian Zhang, Yuxin Mu, Hui Zhang, Chao Deng, Jiao Yang, Lu Gan, Qingmo Yang, Xuefeng Xu, Wanping Liang, Xiaowei Qi, Liang Xu
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
HER2-positive metastatic breast cancer
inetetamab-containing regimens
pyrotinib
pertuzumab
chemotherapy
first-line/second-line therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1564888/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2025.1564888/full

Similar Items